A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Veverimer in Adults With CKD and Metabolic Acidosis (The REVIVE Study)
Latest Information Update: 06 Mar 2026
At a glance
- Drugs Veverimer (Primary)
- Indications Kidney disorders; Metabolic acidosis
- Focus Registrational; Therapeutic Use
- Acronyms REVIVE
- Sponsors Renibus Therapeutics
Most Recent Events
- 19 Feb 2026 Status changed from not yet recruiting to recruiting.
- 28 Jan 2026 New trial record